Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease

Efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors

Significance of gut microbiota in patients receiving CAR T cell immunotherapy

The RxPONDER trial and its impact on best clinical practice

WHO and St. Jude Children’s research hospital to dramatically increase global access to childhood cancer medicine

The global platform for access to childhood cancer medicines

Cancer medicine shortages for children around the world

OncoAlert and ecancer round up: SABCS 2021

INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma